Swaroop S, Biswas S, Mehta S, Aggarwal A, Arora U, Agarwal S, Chavan A, Nayak B, Shalimar.
Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response. Journal of Clinical Medicine. 2025; 14(3):1034.
https://doi.org/10.3390/jcm14031034

Chicago/Turabian Style

Swaroop, Shekhar, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, and Shalimar.
2025. “Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response” Journal of Clinical Medicine 14, no. 3: 1034.
https://doi.org/10.3390/jcm14031034

APA Style

Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar.

(2025). Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response. Journal of Clinical Medicine, 14(3), 1034.
https://doi.org/10.3390/jcm14031034